Prismasol BGK
Clinical Indications
Continuous Renal Replacement Therapy (CRRT) — specifically CVVHDF or CVVH in critically ill patients with acute kidney injury (AKI). Prismasol BGK provides a physiologic, bicarbonate-buffered, potassium-containing replacement/dialysis fluid for haemofiltration.
Dosing & Administration Rate
CRRT dose typically 20–25 mL/kg/hr (effluent dose). Pre-dilution or post-dilution depending on filter life and haematocrit. Bicarbonate buffer provides direct metabolic acidosis correction without the disadvantages of lactate-buffered solutions.
Warnings & Precautions
For CRRT use only — not for standard IV administration. Potassium 4 mEq/L is appropriate for most patients but must be adjusted if hypokalaemia or hyperkalaemia is present. Regional citrate anticoagulation protocols may require citrate-compatible formulations instead. Monitor ionised calcium closely during CRRT.
Contraindications
No absolute contraindications for CRRT. Formulation specific: do not use if patient requires a different electrolyte profile (e.g., hyperkalemic patients should not receive K+-containing fluids).
Pharmacology & Safety Profile
Mechanism of Action
Functions as a dialysate and replacement fluid for Continuous Renal Replacement Therapy (CRRT), clearing toxins while restoring physiologic electrolytes and buffering with bicarbonate/lactate.
Adverse Reactions
Hypothermia, fluid imbalance, electrolyte disturbances (hypophosphatemia, hypomagnesemia), acid-base imbalances.
Compatibility Notes
Compatible with Prismaflex and Multifiltrate CRRT platforms. Consult CRRT clinical pharmacist for anticoagulation compatibility.
Electrolyte & Composition Profile
| Component | Amount / Concentration |
|---|---|
| Sodium (Na⁺) | 140 mEq/L |
| Potassium (K⁺) | 4 mEq/L (B = Bicarbonate, G = Glucose, K = Potassium) |
| Calcium (Ca²⁺) | 1.75 mmol/L (3.5 mEq/L) |
| Magnesium (Mg²⁺) | 0.6 mmol/L |
| Chloride (Cl⁻) | 111.4 mEq/L |
| Bicarbonate (HCO₃⁻) | 32 mEq/L |
| Glucose | 1 g/L (5.5 mmol/L) |
| Water for Injection | q.s. |
Clinical Parameters
Clinical Disclaimer: Data compiled from FDA DailyMed, Baxter/Fresenius prescribing information, and USP monographs. Always verify against the physical product label, your institution's IV protocols, and current pharmacist guidance before administration.
Related IV Solutions in Renal Replacement Therapy Fluid